Clinical Data Key pipeline drug for Lundbeck delivers in Cushing syndrome PharmaphorumLundbeck has reported positive trial results with Cushing's therapy asedebart, a key R D prospect as it faces a patent cliff in the next few years.Rare DiseaseRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) Pharmaphorum Lundbeck has reported positive trial results with Cushing’s therapy asedebart, a key R D prospect as it faces a patent cliff in the next few years. Rare Disease Read full story Post navigation Previous: Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic diseaseNext: Eisai claims UK grant to expand manufacturing site Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026